Integrated Management of atypical Parkinsonism: A home-based patient-Centered healthcare model using Telenursing. Baseline data from the Multicentre IMPACT study
Objective: To evaluate the effectiveness of a telemedicine-based (‘Telenursing’) home healthcare model, coordinated by a Parkinsonism Nurse Specialist (PKNS), in improving the quality of life…A Randomized, Double-blind Phase 3 Trial of Amlenetug Versus Placebo in Patients with MSA: The MASCOT Trial
Objective: Describe the protocol for a randomized, double-blind phase 3 trial evaluating the efficacy and safety of amlenetug versus placebo in slowing clinical progression in…Incorporating Patient and Care Partner Feedback on the Protocol for a Clinical Trial Assessing Progression in MSA
Objective: Describe the perspectives of people living with MSA (PwMSA) and their care partners on the design and operational characteristics of a phase 3 trial…The IMPACT study: protocol of a randomised controlled single-blind trial evaluating efficacy and cost-effectiveness of telenursing in atypical parkinsonism
Objective: To present the protocol of a study evaluating the efficacy and cost-effectiveness of a 12-month integrated program aimed at improving healthcare delivery and coordinated…Intrathecal Administration of Human Oral Mucosa Neural Crest Stem Cells in Moderate/Advanced Multiple System Atrophy: Report on Ongoing Phase 1 Study
Objective: This first-in-human study aims to evaluate the safety of hOMNSC300 following intrathecal administration in patients with moderate to advanced MSA. Background: Stem cell therapy…ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy
Objective: Evaluate the efficacy and safety of ATH434 treatment in individuals with MSA Background: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder without…The effectiveness and safety of autologous adipose derived stromal vascular components (SVF) in the treatment of multiple system atrophy
Objective: This study aimed to explore the efficacy and safety of autologous adipose - derived stromal vascular fraction (SVF) in treating MSA. Background: Multisystem atrophy…A Comprehensive Exploration of the Quality of Life and Caregiver Burden in Multiple System Atrophy
Objective: To evaluate the impact of MSA disease on QoL and caregiver burden and identify influencing factors of QoL in a large UK-based cohort Background:…Differentiated approach to treatment and diagnosis of Parkinson’s disease.
Objective: The anatomical and physiological characteristics of tremor in patients with Parkinson’s disease and essential tremor at the same age significantly influence diagnostic approaches, differentiation…Assessing Disease Progression in MSA: Development of a Bayesian Progression Model
Objective: Develop a Bayesian progression model (BPM) for MSA that leverages individual-level data derived from long-term follow up and offers a clinically interpretable, slope-based primary…
- 1
- 2
- 3
- …
- 8
- Next Page »